CA2753461A1 - Peptide for the prophylactic or therapeutic treatment of skin tumours in initial stages - Google Patents

Peptide for the prophylactic or therapeutic treatment of skin tumours in initial stages Download PDF

Info

Publication number
CA2753461A1
CA2753461A1 CA2753461A CA2753461A CA2753461A1 CA 2753461 A1 CA2753461 A1 CA 2753461A1 CA 2753461 A CA2753461 A CA 2753461A CA 2753461 A CA2753461 A CA 2753461A CA 2753461 A1 CA2753461 A1 CA 2753461A1
Authority
CA
Canada
Prior art keywords
disitertide
peptide
skin
therapeutic treatment
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2753461A
Other languages
English (en)
French (fr)
Inventor
Raul Insa Boronat
Miguel Quintanilla Avila
Javier Dotor De Las Herrerias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Digna Biotech SL
Original Assignee
Isdin SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isdin SA filed Critical Isdin SA
Publication of CA2753461A1 publication Critical patent/CA2753461A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2753461A 2009-03-06 2010-03-04 Peptide for the prophylactic or therapeutic treatment of skin tumours in initial stages Abandoned CA2753461A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200900694A ES2347627B1 (es) 2009-03-06 2009-03-06 Peptido para el tratamiento profilactico o terapeutico de tumores de la piel en estadios iniciales.
ESP200900694 2009-03-06
PCT/ES2010/070121 WO2010100310A1 (es) 2009-03-06 2010-03-04 Péptido para el tratamiento profiláctico o terapéutico de tumores de la piel en estadios iniciales

Publications (1)

Publication Number Publication Date
CA2753461A1 true CA2753461A1 (en) 2010-09-10

Family

ID=42709234

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2753461A Abandoned CA2753461A1 (en) 2009-03-06 2010-03-04 Peptide for the prophylactic or therapeutic treatment of skin tumours in initial stages

Country Status (13)

Country Link
US (1) US8658599B2 (https=)
EP (1) EP2404611A4 (https=)
JP (1) JP2012519671A (https=)
CN (1) CN102341115A (https=)
AR (1) AR075783A1 (https=)
AU (1) AU2010219857A1 (https=)
BR (1) BRPI1013363A8 (https=)
CA (1) CA2753461A1 (https=)
ES (1) ES2347627B1 (https=)
MX (1) MX2011009225A (https=)
RU (1) RU2011140477A (https=)
TW (1) TW201036625A (https=)
WO (1) WO2010100310A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9353149B2 (en) * 2013-05-10 2016-05-31 Southern Research Institute Compounds, compositions and methods for the treatment of diseases through inhibiting TGF-β activity
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
JP5650367B2 (ja) * 2004-02-27 2015-01-07 アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物
WO2007048857A1 (es) * 2005-10-24 2007-05-03 Proyecto De Biomedicina Cima, S.L. USO DE PÉPTIDOS INHIBIDORES DE TGF- βl EN LA PREPARACIÓN DE UN AGENTE MODULADOR DE LA RESPUESTA INMUNE
EP2305309A2 (en) * 2008-06-13 2011-04-06 Proyecto de Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds

Also Published As

Publication number Publication date
ES2347627B1 (es) 2011-10-10
JP2012519671A (ja) 2012-08-30
ES2347627A1 (es) 2010-11-02
MX2011009225A (es) 2011-10-10
RU2011140477A (ru) 2013-04-27
BRPI1013363A2 (pt) 2016-03-29
AU2010219857A1 (en) 2011-10-06
BRPI1013363A8 (pt) 2016-07-19
EP2404611A1 (en) 2012-01-11
CN102341115A (zh) 2012-02-01
US8658599B2 (en) 2014-02-25
US20120065144A1 (en) 2012-03-15
TW201036625A (en) 2010-10-16
EP2404611A4 (en) 2012-11-21
WO2010100310A1 (es) 2010-09-10
AR075783A1 (es) 2011-04-27

Similar Documents

Publication Publication Date Title
Klimek et al. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia
EP0646012B1 (en) WOUND HEALING AND TREATMENT OF FIBROTIC DISORDERS BY TGFbeta-3
EP2152256B1 (en) Telomerase activating compounds and methods of use thereof
EP3252032A1 (en) Diglycidic ether derivative therapeutics and methods for their use
WO2009051801A2 (en) Chemical inhibitors of inhibitors of differentiation
JP6862404B2 (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤
Lin et al. Neuregulin-1, a microvascular endothelial-derived protein, protects against myocardial ischemia-reperfusion injury
EP3922251B1 (en) Cancer immunotheraphy adjuvant
US20190365858A1 (en) Methods and compositions for rejuvenating neuromuscular junctions
US8658599B2 (en) Peptide for the prophylactic or therapeutic treatment of skin tumors in initial stages
US8652540B2 (en) Method of using rhein for treating fibrotic conditions and tumors
KR20230027054A (ko) Cebp-베타 길항제의 투여 및 사용 방법
KR102003153B1 (ko) 레졸빈 d2를 유효성분으로 함유하는 피부 염증 치료용 조성물
EP3654984B1 (en) Topical treatment for preventing and mitigating skin cytotoxicity due to therapy with tyrosine kinase inhibitors
EP3435990B1 (en) Stable pharmaceutical compositions for topical administration and uses thereof
KR20180058843A (ko) 짧은 합성 펩티드 및 그의 용도
JP5923375B2 (ja) Ｃｇｒｐ応答性促進剤
US20170273938A1 (en) Use of flavonoids in manufacturing compositions for wound healing
US8846652B2 (en) Therapeutic uses of steroidal compounds
KR102575465B1 (ko) 도세탁셀 및 칼키톡신 티올아마이드를 유효성분으로 함유하는 암 전이 억제 및/또는 암 치료 효과 증진용 조성물
KR102230271B1 (ko) 지방감소를 위한 글라이코데옥시콜릭산 (Glycodeoxycholic acid, GDCA)를 유효성분으로 포함하는 주사용 제제 및 조성물
KR102065150B1 (ko) 이소트레티노인-펩타이드 결합체를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물
WO2017049194A1 (en) Compositions and method for regulating adipose tissue lipolysis, insulin-resistance, and hyperglycemia
KR20240167400A (ko) 염증성 피부 질환의 예방 또는 치료용 조성물
Tatiana et al. McCune-Albright syndrome (MAS): clinical case

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160304